Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing Potential
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Oliver McCammon reaffirmed a Buy rating on Aura Biosciences with an unchanged $23 price target. He cites bel-sar's potential to offer vision-sparing treatment for early choroidal melanoma as a key driver, contrasting it with current radiation therapies that risk vision loss. With the Phase 3 CoMpass trial fully enrolled and pivotal data expected in 2027, McCammon views the stock as having an attractive risk-reward profile.
Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc, retaining the price target of $23.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Oliver McCammon has given his Buy rating due to a combination of factors, chiefly the potential of bel-sar to reshape treatment for early choroidal melanoma. His work with ocular oncology specialists highlights that current radiation-based care, while effective at local tumor control, carries a substantial and often unacceptable risk of long-term vision loss for many patients.
He views bel-sar’s targeted, light-activated mechanism as well positioned to offer a vision-sparing, outpatient alternative for small tumors and indeterminate lesions, addressing both overtreatment and delayed intervention risks identified by experts. With the Phase 3 CoMpass trial fully enrolled and pivotal data expected in 2027, alongside an unchanged $23 price target, he believes Aura Biosciences offers an attractive risk-reward profile at current levels.
According to TipRanks, McCammon is a 5-star analyst with an average return of 78.7% and a 52.54% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Celcuity, Corbus Pharmaceuticals, and Aura Biosciences Inc.